NEW YORK – June 4, 2018 – Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces the initiation of an investigator-initiated trial at Virginia Commonwealth University Medical Center that will incorporate the company’s patented BVA-100 diagnostic to assess blood volume loss during burn surgery.
“Intravascular volume and red cell mass management are unquestionably important determinants of outcomes in critically ill patients. More so than others, burn patients represent a particularly vulnerable population to significant volume/red cell derangements. Current tools used in the management of these patients including urine output, vital signs and peripheral hematocrits are not sensitive enough. We look forward to assessing the impact of a measure designed specifically for blood volume in the context of burn surgery with the hope that it may increase survival outcomes,” said Mark Nelson, MD, the trial’s principal investigator and chief, Division of Cardiothoracic Anesthesiology, Department of Anesthesiology at Virginia Commonwealth University School of Medicine, Richmond, Va. “We look forward to assessing the impact of a measure designed specifically for blood volume in the context of burn surgery with the hope that it may increase survival outcomes.”
The BVA-100 device has been shown to reduce sepsis and shock deaths in prior clinical studies, including a 2011 paper that demonstrated a 66 percent reduction in mortality. Burn patients undergoing graft surgery generally experience significant blood loss and fluid imbalance, both of which bring about these co-morbidities. The trial will be conducted wholly by Virginia Commonwealth University Medical Center under the direction of Dr. Nelson.
“We believe conducting this additional trial with Dr. Nelson to help cement understanding of the benefits of BVA in the context of burn surgery will provide physicians with irrefutable evidence that our blood volume measurement will indeed save countless lives,” said Michael Feldschuh, CEO of Daxor. “We look forward to sharing these results both with medical professionals and our shareholders.”
Daxor Corporation is an innovative medical instrumentation and biotechnology company. We manufacture the BVA-100 Blood Volume Analyzer, the first instrument approved by the FDA to provide rapid direct measurement of a patient’s blood volume. We believe that the BVA-100 Blood Volume Analyzer has the potential to transform therapy in a broad range of surgical and medical conditions. It is our goal, working in conjunction with hospitals and clinics, to achieve that possibility. Ultimately the company’s mission is to help hospitals and physicians incorporate DAXOR’s advanced technologies to significantly improve the quality of patient care. For more information please visit our website at https://www.daxor.com.
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact Information: Daxor Corporation Soren Thompson Investor Relations 212-330-8502 email@example.com Investor Relations Contact: Bret Shapiro Sr. Managing Director CORE IR 561-479-8566 firstname.lastname@example.org Media: Jules Abraham COREIR 917-885-7378 email@example.com